Amgen, Inc. (NASDAQ:AMGN) – Stock analysts at William Blair boosted their FY2018 EPS estimates for Amgen in a research note issued on Wednesday, October 31st. William Blair analyst M. Phipps now anticipates that the medical research company will post earnings per share of $14.25 for the year, up from their previous forecast of $13.91. William Blair also issued estimates for Amgen’s Q4 2018 earnings at $3.26 EPS, Q1 2019 earnings at $3.59 EPS, Q2 2019 earnings at $3.65 EPS, Q3 2019 earnings at $3.56 EPS, Q4 2019 earnings at $3.58 EPS, FY2019 earnings at $14.38 EPS and FY2020 earnings at $14.72 EPS.
A number of other equities analysts also recently commented on AMGN. JPMorgan Chase & Co. increased their price objective on shares of Amgen from $191.00 to $192.00 and gave the stock a “neutral” rating in a research note on Friday, July 27th. BidaskClub upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 11th. Jefferies Financial Group restated a “buy” rating and set a $200.00 price objective on shares of Amgen in a research note on Monday, July 16th. Goldman Sachs Group restated a “buy” rating and set a $221.00 price objective on shares of Amgen in a research note on Wednesday, October 31st. Finally, Cantor Fitzgerald restated a “hold” rating and set a $223.00 price objective on shares of Amgen in a research note on Wednesday, October 31st. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $204.55.
Amgen stock opened at $190.75 on Monday. Amgen has a one year low of $163.31 and a one year high of $210.19. The company has a debt-to-equity ratio of 2.05, a current ratio of 3.08 and a quick ratio of 2.84. The stock has a market cap of $119.20 billion, a PE ratio of 15.16, a price-to-earnings-growth ratio of 1.95 and a beta of 1.37.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, October 30th. The medical research company reported $3.69 EPS for the quarter, topping the Zacks’ consensus estimate of $3.45 by $0.24. Amgen had a net margin of 9.44% and a return on equity of 54.14%. The company had revenue of $5.90 billion during the quarter, compared to the consensus estimate of $5.78 billion. During the same period in the prior year, the business posted $3.27 EPS. The company’s quarterly revenue was up 2.3% on a year-over-year basis.
Large investors have recently modified their holdings of the stock. Kwmg LLC bought a new position in Amgen in the 2nd quarter valued at about $108,000. Mainstay Capital Management LLC ADV bought a new position in Amgen in the 2nd quarter valued at about $111,000. Polaris Greystone Financial Group LLC bought a new position in shares of Amgen during the third quarter worth approximately $166,000. Wellington Shields Capital Management LLC bought a new position in shares of Amgen during the third quarter worth approximately $202,000. Finally, SignalPoint Asset Management LLC bought a new position in shares of Amgen during the third quarter worth approximately $205,000. Institutional investors and hedge funds own 82.37% of the company’s stock.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 7th. Investors of record on Friday, November 16th will be paid a $1.32 dividend. The ex-dividend date is Thursday, November 15th. This represents a $5.28 annualized dividend and a yield of 2.77%. Amgen’s dividend payout ratio (DPR) is currently 41.97%.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Featured Article: How accurate is the Rule of 72?
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.